Related Experiment Video
Updated: Jun 8, 2026
12:21
Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
The ABCB1 transporter gene and antidepressant response
Eric J Peters1, Victor Reus, Steven P Hamilton
1Illumina Inc, 9865 Towne Centre Drive, San Diego, CA 92121-1975, USA.
F1000 Biology Reports
|October 16, 2010
Summary
Genetic variations in the ABCB1 gene, which encodes P-glycoprotein, may affect how well antidepressants work by influencing their brain concentrations. This review examines studies linking ABCB1 gene variations to antidepressant treatment response.
Area of Science:
- Pharmacogenetics
- Neuroscience
- Molecular Biology
Background:
- P-glycoprotein, an efflux transporter encoded by the ABCB1 gene, plays a role in the blood-brain barrier.
- ABCB1 gene variants are hypothesized to influence the brain penetration and efficacy of various antidepressant medications.
Purpose of the Study:
- To review existing research investigating the association between functional genetic variations in the ABCB1 gene and clinical response to antidepressant therapy.
- To synthesize current evidence on the role of P-glycoprotein in antidepressant pharmacodynamics.
Main Methods:
- Literature review of studies examining ABCB1 gene polymorphisms and their correlation with antidepressant treatment outcomes.
- Analysis of data from clinical trials and observational studies.
Main Results:
- Evidence suggests a potential link between specific ABCB1 genetic variations and variable responses to certain antidepressants.
- The impact of P-glycoprotein activity on antidepressant pharmacokinetics and pharmacodynamics is complex and requires further elucidation.
Conclusions:
- Functional genetic variation in the ABCB1 gene may contribute to inter-individual differences in antidepressant efficacy.
- Further research is warranted to fully understand the clinical implications of ABCB1 polymorphisms for personalized antidepressant treatment strategies.
Related Concept Videos
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:31ABC Transporters: Exporter
ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
01:27ABC Transporters: Importer
ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...